GlassScriptPhysician profile
Julie A Spears
NPI 1720388846
$5,713.97
in general payments reported to CMS, 2019-2025
46 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 93% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
See the full distribution for Acute Care (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $571 · 2023: $1,352 · 2024: $1,424 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,077 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,077.35 |
| Education | $336.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,220.06 | 2021-2025 | Calquence, Imfinzi, Datroway |
| Janssen Biotech, INC. | $559.41 | 2021-2025 | Talvey, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $483.39 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $329.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $237.50 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $218.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.70 | 2021-2024 | Opdivo |
| Acrotech Biopharma INC. | $153.80 | 2021 | |
| Caris Mpi, INC. | $140.77 | 2025 | Mi Cancer Seek |
| Seagen INC. | $132.07 | 2021-2023 | Adcetris |
| Genzyme Corporation | $129.61 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $121.79 | 2022 | |
| Incyte Corporation | $118.22 | 2023-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $111.47 | 2025 | |
| Myriad Genetic Laboratories, INC. | $110.70 | 2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $109.26 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $101.61 | 2022-2025 | |
| Exelixis INC. | $99.99 | 2023 | |
| Aveo Pharmaceuticals, INC. | $77.94 | 2021-2024 | Fotivda |
| Gilead Sciences, INC. | $73.12 | 2022-2024 | Trodelvy |
| Dendreon Pharmaceuticals LLC | $68.62 | 2022-2025 | Provenge |
| Amgen INC. | $65.75 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Genentech USA, INC. | $62.19 | 2022-2023 | Venclexta, Lunsumio, Tecentriq |
| Ipsen Biopharmaceuticals, INC | $61.11 | 2025 | Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $59.39 | 2021-2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $59.38 | 2023-2025 | Libtayo |
| Celgene Corporation | $58.95 | 2021 | |
| Sobi, INC | $49.44 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $47.34 | 2024-2025 | Enjaymo, Sylvant |
| Lilly USA, LLC | $47.19 | 2022-2025 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $47.01 | 2023-2024 | Zoladex |
| Eisai INC. | $46.10 | 2022-2024 | |
| Puma Biotechnology, INC. | $39.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.51 | 2024-2025 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $34.64 | 2022-2024 | Ultomiris |
| Genmab U.S., INC. | $33.16 | 2024 | Epkinly |
| Foundation Medicine, INC. | $22.44 | 2023 | Foundationone Cdx |
| Novo Nordisk INC | $21.58 | 2022 | |
| Astellas Pharma US INC | $21.47 | 2024 | Padcev |
| Mirati Therapeutics, INC. | $18.99 | 2024 | Krazati |
| Epizyme, INC. | $18.72 | 2021 | |
| Rigel Pharmaceuticals, INC. | $18.69 | 2021 | |
| G1 Therapeutics, INC. | $16.93 | 2022 | |
| Geron Corporation | $14.96 | 2024 | Rytelo |
| Secura Bio, INC. | $14.08 | 2025 | Copiktra |
| Jazz Pharmaceuticals INC. | $13.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.